Clinical Trial to Evaluate the Safety and Efficacy of Scalp Med(R) in Treatment of Patients with Androgenetic Alopecia.
- Author:
Bark Lynn LEW
1
;
Woo Young SIM
;
Chang Hun HUH
;
Jang Kyu PARK
Author Information
1. Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea.
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Androgenetic alopecia;
Minoxidil;
Scalp med
- MeSH:
Alopecia;
Finasteride;
Hair;
Hair Follicle;
Humans;
Male;
Miniaturization;
Minoxidil;
Polysorbates;
Scalp;
Vitamin A
- From:Korean Journal of Dermatology
2008;46(6):776-783
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Androgenetic alopecia (AGA) is characterized by the structural miniaturization of androgen-sensitive hair follicles in susceptible individuals and is anatomically defined within a given pattern of the scalp. Oral finasteride and topical minoxidil are the only drugs whose effect and safety were demonstrated and approved by the FDA. However, the treatment result of these medications are not always satisfactory. Here, we report the result of a clinical trial of the new topical agent, Scalp med(R) to patients with AGA. OBJECTIVE: The goal of this study was to test Scalp med(R), the solution including minoxidil, retinol, polysorbate 80 and phytosterol in the treatment of AGA. METHODS: Included in this study were males between the ages of 20 and 60 years, in good health, with mild to moderate AGA. Efficacy was evaluated by terminal hair count per 1 cm2 and hair thickness. RESULTS: The results of this clinical trial showed a highly positive response to treatment. After 24 weeks of treatment, a significant improvement in hair count and hair thickness was demonstrated in all the patients. CONCLUSION: This clinical study establishes the effectiveness and safety of Scalp med(R) in the treatment of AGA.
